# Fazirsiran PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/fazirsiran

> The next catalyst for fazirsiran, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), is its topline data readout, Aug to Nov 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | fazirsiran |
| Codes | TAK-999, ADS-001 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [Alpha1-Antitrypsin Deficiency](https://sec-api.dev/indications/alpha1-antitrypsin-deficiency) |
| Modality | sirna |
| FDA designations | breakthrough, fast track |

## Timeline

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alpha1-Antitrypsin Deficiency.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06165341 (Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-26 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06165341

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alpha1-Antitrypsin Deficiency.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06165341 (Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-26 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06165341

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alpha1-Antitrypsin Deficiency.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05677971 (Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-17 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT05677971

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alpha1-Antitrypsin Deficiency.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05677971 (Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-17 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT05677971

Calendar months: [August 2028](https://sec-api.dev/fda-calendar/2028-08)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/fazirsiran.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Fazirsiran PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/fazirsiran

```bibtex
@misc{secapidev_pdufa_fazirsiran_20261116,
  title        = {Fazirsiran PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/fazirsiran}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_fazirsiran_20261116","title":"Fazirsiran PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/fazirsiran","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
